Quarterly report · Q3
4886.TEDINET S100Q4CE
Period2022-04-01 → 2022-12-31
Filed2023-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥47.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥44.2bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥5.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥4.7bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.8bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥4.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥90.8bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥87.5bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥36.7bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥54.1bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.5bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥148.19 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥143.76 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥242.1 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.3% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥196m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥155m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | −¥26m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥41m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥767m |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥417m |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥41.9bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥41.9bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥47.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥47.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥41m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-12-31 | ¥158m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-12-31 | ¥116m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-12-31 | −¥42m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥41m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥495m |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥4.4bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥4.4bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥329m |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥39.7bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥39.7bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥44.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥44.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥41m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥5.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 340
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 5538000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 39685000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 4377000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 116000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 44179000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 44179000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 41000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 41000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -41000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 39685000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 4377000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 158000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 44221000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -41000000 | JPY |
| Net sales | Prior1YTDDuration | 44179000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 4886000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 329000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -42000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 5173000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -495000000 | JPY |
| Operating income | Prior1YTDDuration | 4677000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 41916000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 5187000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 155000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 47259000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 47259000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 41000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 41000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -41000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 41916000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 5187000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 196000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 47300000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -41000000 | JPY |
| Net sales | CurrentYTDDuration | 47259000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 5418000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 417000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -26000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 5809000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -767000000 | JPY |
| Operating income | CurrentYTDDuration | 5041000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |